| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_14f0968980e2510a2cc14ac26baebb88 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2217-05 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-43595
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K67-0271
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-0047
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-0041 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-435
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01K67-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01K67-027
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09 |
| filingDate |
2004-08-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bc6c08639d2b7b679ef6ad5d16bb4290
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_401bf9e3c021f4be3857d1df3c8a643b |
| publicationDate |
2005-01-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2005006660-A |
| titleOfInvention |
Cancer metastasis model using green fluorescent protein (GFP) as a marker |
| abstract |
PROBLEM TO BE SOLVED: To provide a method for tracking the progress of metastasis of a primary tumor. The method of the present invention removes fresh organ tissue from a vertebrate subject that has been modified to contain tumor cells that express GFP, and observes the presence of fluorescence in the excised tissue. Comprising that. Fluorescence can also be monitored by observing the tissue in situ. Vertebrate subjects containing GFP-producing tumors are useful models for studying the mechanism of metastasis. In addition, a subject already having a tumor can be treated to modify the tumor that has developed therein to have GFP. This allows clinical application. Finally, angiogenesis in the tumor can be directly observed by injecting a counterstained dye into a subject with a GFP-labeled tumor. [Selection figure] None |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8493854-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8165596-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8189537-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8369865-B2 |
| priorityDate |
1997-04-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |